%0 Journal Article
%T Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
%A Antunes, Liliana
%A Mazagatos, Clara
%A Martínez-Baz, Iván
%A Gomez, Verónica
%A Borg, Maria-Louise
%A Petrović, Goranka
%A Duffy, Róisín
%A Dufrasne, François E.
%A Dürrwald, Ralf
%A Lazar, Mihaela
%A Jancoriene, Ligita
%A Oroszi, Beatrix
%A Husa, Petr
%A Howard, Jennifer
%A Melo, Aryse
%A Pozo, Francisco
%A Pérez-Gimeno, Gloria
%A Castilla, Jesús
%A Machado, Ausenda
%A Džiugytė, Aušra
%A Karabuva, Svjetlana
%A Fitzgerald, Margaret
%A Fierens, Sébastien
%A Tolksdorf, Kristin
%A Popovici, Silvia-Odette
%A Mickienė, Auksė
%A Túri, Gergő
%A Součková, Lenka
%A Nicolay, Nathalie
%A Rose, Angela M.C.
%A on behalf of the European Hospital Vaccine Effectiveness Group
%D 2024
%G eng
%X We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.
%K COVID-19
%K COVID-19 bivalent vaccines
%K Europe
%K Hospitalisation
%K SARI
%K SARS-CoV-2
%K Vaccine effectiveness
%K XBB
%K 610 Medizin und Gesundheit
%I Robert Koch-Institut
%J Eurosurveillance - Europe's journal on infectious disease surveillance, epidemiology, prevention and control
%P 1--8
%R 10.2807/1560-7917.ES.2024.29.3.2300708